Thanks to @ajuloorimd, @mkorps42, @RohanKatipally, @SeanPitroda, @Docace911, @ChristineBestv1, @jasonlukemd, and @JPatelMD for contributions to this work!.

We found rates of toxicity were similar to those seen in major trials of ICI alone, suggesting that SBRT adds minimal toxicity (consistent with low rates of SBRT tox in SABR-5 and recently OligoCare). Critically, standard SBRT constraints were used with priority on OAR sparing.

Note that many other trials in this space have treated just a single lesion and/or used lower-dose treatments to stimulate an immune response. Our protocols treated 1-4 mets to a BED >100 Gy (except in bone) which we feel is closer to typical clinical use of SBRT for optimal LC.

Online now: our report in EJC compiles toxicity data from 213 pts across 3 multi-site SBRT + immune checkpoint inhibitor trials at UChicago to characterize the toxicity profile of combined modality treatment:

RT @TheLancetOncol: New Review in the August issue: Radiotherapy, immunity, and immune checkpoint inhibitors. #radiotherapy #ImmuneCheckpoi….

Considering negative trials of radiation and immunotherapy in light of available preclinical and translational data. Our review of this rapidly evolving field:

Could we hold off on checkpoint inhibitors in patients with low-volume metastatic disease and treat with local therapy instead? Our editorial exploring this idea: (thanks to @rweichselbaum @MuzamilArshad18 @RohanKatipally @SeanPitroda).

More interesting findings from UChicago Chem and Rad Onc (@rweichselbaum lab) on STING activation and the tumor microenvironment

RT @ConnorLynchMD: @ajuloorimd @UCCancerCenter Thanks for the shoutout! One of the great things about training @UChicagoRadonc is working w….